Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RP-6306 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RP-6306 + Gemcitabine | ACTIVE_COMPARATOR | - |
| RP-6306 + FOLFIRI | ACTIVE_COMPARATOR | - |
| RP-6306 + Trastuzumab | ACTIVE_COMPARATOR | - |
| RP-6306 + RP-3500 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| RP-6306 | DRUG | Dose and schedule will be assigned at enrolment |
| Gemcitabine | DRUG | Dose and schedule will be assigned at enrolment |
| FOLFIRI Protocol | DRUG | Irinotecan Leucovorin FU |
| Trastuzumab | DRUG | standard doses q3weekly |
| RP-3500 | DRUG | Dose and schedule will be assigned at enrolment |
Inclusion Criteria: * Patients must have histologically confirmed cancer, that is advanced/metastatic/recurrent or unresectable, for which no curative therapy exists, and be eligible for one or more of the open cohorts * All patients must have a formalin fixed paraffin embedded tissue block (from p...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
RP-6306 is an investigational small molecule being developed for the treatment of advanced cancer. It is a targeted therapy studied in patients with advanced solid tumors, with a focus on biomarker-selected populations. As of the latest data, it is in Phase 2 clinical development and is not yet approved by regulatory authorities.
RP-6306 is a small molecule designed to target specific molecular pathways involved in cancer cell growth. It is being studied in biomarker-selected patients, meaning its activity is expected to be most relevant in tumors with particular genetic alterations. The exact molecular target is not disclosed in the available information.
RP-6306 is being developed by Repare Therapeutics Inc., a biopharmaceutical company focused on precision oncology. The company's stock is traded under the ticker symbol RPTX. Repare Therapeutics is conducting clinical trials to evaluate the safety and efficacy of RP-6306 in patients with advanced cancer.
RP-6306 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied in patients with advanced cancer, and its safety and efficacy are still being evaluated in clinical trials.
RP-6306 has been studied in a Phase 2 clinical trial with the identifier NCT05605509, titled 'RP-6306 in Patients With Advanced Cancer.' This trial enrolled 28 participants in Canada and has been completed. The study was active-controlled and included patients aged 18 years and older with advanced cancer.
No alternative names for RP-6306 have been reported. It is a unique investigational compound developed by Repare Therapeutics Inc. and is not known to be identical to any other marketed or investigational drug.